Wealthcare Advisory Partners LLC Has $2.44 Million Stake in Gilead Sciences, Inc. $GILD

Wealthcare Advisory Partners LLC trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 20.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 19,347 shares of the biopharmaceutical company’s stock after selling 4,992 shares during the period. Wealthcare Advisory Partners LLC’s holdings in Gilead Sciences were worth $2,444,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of GILD. Shrier Wealth Management LLC boosted its position in shares of Gilead Sciences by 1.0% during the second quarter. Shrier Wealth Management LLC now owns 14,201 shares of the biopharmaceutical company’s stock worth $1,794,000 after buying an additional 135 shares during the period. Revolve Wealth Partners LLC raised its position in Gilead Sciences by 52.3% in the 2nd quarter. Revolve Wealth Partners LLC now owns 5,473 shares of the biopharmaceutical company’s stock valued at $691,000 after buying an additional 1,880 shares during the last quarter. Contravisory Investment Management Inc. lifted its stake in Gilead Sciences by 2.6% in the 2nd quarter. Contravisory Investment Management Inc. now owns 5,737 shares of the biopharmaceutical company’s stock valued at $725,000 after acquiring an additional 143 shares in the last quarter. Sapient Capital LLC boosted its position in Gilead Sciences by 1.4% during the 2nd quarter. Sapient Capital LLC now owns 165,115 shares of the biopharmaceutical company’s stock worth $20,861,000 after acquiring an additional 2,289 shares during the last quarter. Finally, Allied Private Wealth LLC acquired a new position in Gilead Sciences during the 2nd quarter worth approximately $57,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the sale, the insider owned 125,779 shares of the company’s stock, valued at $16,513,524.91. This trade represents a 18.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the transaction, the chief executive officer directly owned 592,133 shares of the company’s stock, valued at approximately $77,160,851.23. This trade represents a 2.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 82,000 shares of company stock worth $10,641,790. 0.30% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on GILD shares. HSBC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their price target for the stock from $133.00 to $155.00 in a research note on Monday, July 6th. Daiwa Securities Group reduced their target price on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, May 19th. Royal Bank Of Canada raised their target price on shares of Gilead Sciences from $120.00 to $123.00 and gave the company a “sector perform” rating in a research report on Wednesday, August 5th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $155.00 price target on shares of Gilead Sciences in a research note on Wednesday, August 5th. Finally, Morgan Stanley cut their price target on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating on the stock in a research report on Monday, July 27th. Twenty-four equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $158.04.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead is partnering with Nucleai to deploy AI-powered tissue analytics across its global antibody-drug conjugate programs. The technology could accelerate biomarker discovery, standardize tumor-sample analysis and improve precision-oncology development, potentially strengthening Gilead’s longer-term pipeline. Gilead Sciences Expands ADC Research With AI Tissue Analytics
• Positive Sentiment: Gilead exercised an option to exclusively license a preclinical bispecific program from MacroGenics, triggering a $10 million payment to its partner. The move expands Gilead’s oncology assets and signals continued investment in potential next-generation cancer treatments, although the program remains early stage. MacroGenics Announces $10 Million Milestone Following Gilead License
• Positive Sentiment: Analysts cited a consensus price target of $158.04, indicating potential upside relative to recent trading levels and continued confidence among covering analysts. Gilead Receives $158.04 Consensus Target Price
• Positive Sentiment: Gilead’s second-quarter revenue rose approximately 10% year over year to $7.8 billion and exceeded expectations. The reported loss was primarily affected by an $11.2 billion one-time acquired in-process research and development write-off, while adjusted results were better than consensus. GILD Attractive Biotech Stock With Solid Base Revenue Growth
• Neutral Sentiment: Unusually heavy call-option buying points to increased bullish trading interest, but options activity is speculative and does not by itself change Gilead’s fundamentals.
• Neutral Sentiment: Coverage of Gilead’s second-quarter earnings call may provide additional details on pipeline progress and management priorities, though no specific new financial catalyst was provided in the supplied report. Analyst Questions From Gilead’s Q2 Earnings Call
• Negative Sentiment: Erste Group Bank slightly reduced its FY2026 EPS forecast to a $0.75 loss from a $0.74 loss and trimmed its FY2027 estimate to $9.57 from $9.59. Although the changes are small, they indicate mildly softer expectations and contrast with the $0.50 consensus loss forecast for the current year.

Gilead Sciences Stock Up 0.1%

Shares of GILD stock opened at $135.87 on Thursday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The firm’s 50-day moving average is $129.75 and its 200-day moving average is $136.42. The stock has a market cap of $168.47 billion, a price-to-earnings ratio of -50.89 and a beta of 0.32. Gilead Sciences, Inc. has a 52-week low of $108.46 and a 52-week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. During the same period last year, the business posted $2.01 EPS. Gilead Sciences’s revenue was up 10.6% on a year-over-year basis. Sell-side analysts predict that Gilead Sciences, Inc. will post -0.53 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently -122.85%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.